ZA200703196B - Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof - Google Patents
Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereofInfo
- Publication number
- ZA200703196B ZA200703196B ZA200703196A ZA200703196A ZA200703196B ZA 200703196 B ZA200703196 B ZA 200703196B ZA 200703196 A ZA200703196 A ZA 200703196A ZA 200703196 A ZA200703196 A ZA 200703196A ZA 200703196 B ZA200703196 B ZA 200703196B
- Authority
- ZA
- South Africa
- Prior art keywords
- tyrosine kinase
- protein tyrosine
- epothilones
- combinations
- kinase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63183704P | 2004-11-30 | 2004-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200703196B true ZA200703196B (en) | 2009-08-26 |
Family
ID=36118322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200703196A ZA200703196B (en) | 2004-11-30 | 2007-04-18 | Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20080139587A1 (sl) |
| EP (1) | EP1819331B1 (sl) |
| JP (1) | JP2008521826A (sl) |
| KR (1) | KR20070088653A (sl) |
| CN (1) | CN101065127A (sl) |
| AT (1) | ATE445398T1 (sl) |
| AU (1) | AU2005312061B2 (sl) |
| BR (1) | BRPI0518733A2 (sl) |
| CA (1) | CA2584163A1 (sl) |
| CY (1) | CY1110559T1 (sl) |
| DE (1) | DE602005017181D1 (sl) |
| DK (1) | DK1819331T3 (sl) |
| ES (1) | ES2333348T3 (sl) |
| HK (1) | HK1109059A1 (sl) |
| HR (1) | HRP20100012T1 (sl) |
| IL (1) | IL183138A (sl) |
| JO (1) | JO2596B1 (sl) |
| MA (1) | MA29032B1 (sl) |
| MX (1) | MX2007006371A (sl) |
| NO (1) | NO20073370L (sl) |
| NZ (1) | NZ554552A (sl) |
| PL (1) | PL1819331T3 (sl) |
| PT (1) | PT1819331E (sl) |
| RU (1) | RU2423980C2 (sl) |
| SI (1) | SI1819331T1 (sl) |
| TN (1) | TNSN07212A1 (sl) |
| TW (1) | TW200630091A (sl) |
| WO (1) | WO2006060331A1 (sl) |
| ZA (1) | ZA200703196B (sl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201200617A1 (ru) | 2009-11-23 | 2012-11-30 | Серулин Фарма Инк. | Полимеры на основе циклодекстрина для доставки лекарственных средств |
| US20110178287A1 (en) | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| EP2571525A4 (en) | 2010-05-18 | 2016-04-27 | Cerulean Pharma Inc | Compositions and methods for treating autoimmune and other diseases |
| CN102134246A (zh) * | 2011-01-06 | 2011-07-27 | 王文怡 | 一种埃博霉素衍生物及其制备和药物应用 |
| US20130178520A1 (en) | 2011-12-23 | 2013-07-11 | Duke University | Methods of treatment using arylcyclopropylamine compounds |
| WO2014025395A1 (en) | 2012-08-06 | 2014-02-13 | Duke University | Compounds and methods for targeting hsp90 |
| WO2015148714A1 (en) | 2014-03-25 | 2015-10-01 | Duke University | Heat shock protein 70 (hsp-70) receptor ligands |
| WO2017184956A1 (en) | 2016-04-22 | 2017-10-26 | Duke University | Compounds and methods for targeting hsp90 |
| US10207998B2 (en) | 2016-09-29 | 2019-02-19 | Duke University | Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof |
| US10927083B2 (en) | 2016-09-29 | 2021-02-23 | Duke University | Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase |
| EP3826988A4 (en) | 2018-07-24 | 2023-03-22 | Hygia Pharmaceuticals, LLC | COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER |
| WO2021185844A1 (en) | 2020-03-16 | 2021-09-23 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
| WO2021233534A1 (en) | 2020-05-20 | 2021-11-25 | Pvac Medical Technologies Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
| US20230285576A1 (en) | 2020-08-05 | 2023-09-14 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
| WO2022047259A1 (en) | 2020-08-28 | 2022-03-03 | California Institute Of Technology | Synthetic mammalian signaling circuits for robust cell population control |
| GB2617409B (en) | 2022-04-27 | 2024-06-26 | Cancertain Ltd | Method for predicting responsiveness to therapy |
| WO2024030441A1 (en) | 2022-08-02 | 2024-02-08 | National University Corporation Hokkaido University | Methods of improving cellular therapy with organelle complexes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| US20040034026A1 (en) * | 2000-11-22 | 2004-02-19 | Wood Jeannette M | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| KR100848197B1 (ko) * | 2001-02-27 | 2008-07-24 | 노파르티스 아게 | 신호 전달 억제제 및 에포틸론 유도체를 포함하는 배합물 |
| GB0119249D0 (en) * | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
| ES2295428T3 (es) * | 2001-10-25 | 2008-04-16 | Novartis Ag | Combinaciones que comprenden un inhibidor selectivo de ciclooxigenasa-2. |
| MXPA04012444A (es) * | 2002-06-10 | 2005-04-19 | Novartis Ag | Combinaciones que comprenden epotilonas y sus usos farmaceuticos. |
| AU2003248813A1 (en) * | 2002-07-05 | 2004-01-23 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
-
2005
- 2005-11-24 JO JO2005184A patent/JO2596B1/en active
- 2005-11-28 DK DK05852316T patent/DK1819331T3/da active
- 2005-11-28 ES ES05852316T patent/ES2333348T3/es active Active
- 2005-11-28 EP EP05852316A patent/EP1819331B1/en active Active
- 2005-11-28 DE DE602005017181T patent/DE602005017181D1/de active Active
- 2005-11-28 JP JP2007543578A patent/JP2008521826A/ja active Pending
- 2005-11-28 AU AU2005312061A patent/AU2005312061B2/en not_active Ceased
- 2005-11-28 MX MX2007006371A patent/MX2007006371A/es active IP Right Grant
- 2005-11-28 WO PCT/US2005/042975 patent/WO2006060331A1/en active Application Filing
- 2005-11-28 CA CA002584163A patent/CA2584163A1/en not_active Abandoned
- 2005-11-28 SI SI200530886T patent/SI1819331T1/sl unknown
- 2005-11-28 BR BRPI0518733-8A patent/BRPI0518733A2/pt not_active IP Right Cessation
- 2005-11-28 CN CNA2005800406122A patent/CN101065127A/zh active Pending
- 2005-11-28 KR KR1020077012081A patent/KR20070088653A/ko not_active Application Discontinuation
- 2005-11-28 NZ NZ554552A patent/NZ554552A/en not_active IP Right Cessation
- 2005-11-28 US US11/718,927 patent/US20080139587A1/en not_active Abandoned
- 2005-11-28 PT PT05852316T patent/PT1819331E/pt unknown
- 2005-11-28 RU RU2007124492/15A patent/RU2423980C2/ru not_active IP Right Cessation
- 2005-11-28 PL PL05852316T patent/PL1819331T3/pl unknown
- 2005-11-28 AT AT05852316T patent/ATE445398T1/de active
- 2005-11-29 TW TW094141943A patent/TW200630091A/zh unknown
-
2007
- 2007-04-18 ZA ZA200703196A patent/ZA200703196B/xx unknown
- 2007-05-10 IL IL183138A patent/IL183138A/en not_active IP Right Cessation
- 2007-05-22 MA MA29923A patent/MA29032B1/fr unknown
- 2007-05-29 TN TNP2007000212A patent/TNSN07212A1/fr unknown
- 2007-06-29 NO NO20073370A patent/NO20073370L/no not_active Application Discontinuation
- 2007-12-21 HK HK07114046.8A patent/HK1109059A1/xx not_active IP Right Cessation
-
2009
- 2009-11-25 CY CY20091101227T patent/CY1110559T1/el unknown
-
2010
- 2010-01-11 HR HR20100012T patent/HRP20100012T1/hr unknown
-
2011
- 2011-04-13 US US13/085,519 patent/US20110190312A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL183138A0 (en) | 2008-04-13 |
| KR20070088653A (ko) | 2007-08-29 |
| PL1819331T3 (pl) | 2010-03-31 |
| BRPI0518733A2 (pt) | 2008-12-02 |
| MA29032B1 (fr) | 2007-11-01 |
| DE602005017181D1 (de) | 2009-11-26 |
| NO20073370L (no) | 2007-06-29 |
| CN101065127A (zh) | 2007-10-31 |
| CY1110559T1 (el) | 2015-04-29 |
| EP1819331B1 (en) | 2009-10-14 |
| IL183138A (en) | 2011-03-31 |
| US20110190312A1 (en) | 2011-08-04 |
| ATE445398T1 (de) | 2009-10-15 |
| HRP20100012T1 (hr) | 2010-02-28 |
| MX2007006371A (es) | 2007-06-20 |
| RU2423980C2 (ru) | 2011-07-20 |
| PT1819331E (pt) | 2009-11-30 |
| TW200630091A (en) | 2006-09-01 |
| CA2584163A1 (en) | 2006-06-08 |
| ES2333348T3 (es) | 2010-02-19 |
| WO2006060331A1 (en) | 2006-06-08 |
| RU2007124492A (ru) | 2009-04-10 |
| AU2005312061B2 (en) | 2009-09-03 |
| AU2005312061A1 (en) | 2006-06-08 |
| US20080139587A1 (en) | 2008-06-12 |
| HK1109059A1 (en) | 2008-05-30 |
| NZ554552A (en) | 2011-05-27 |
| DK1819331T3 (da) | 2010-01-04 |
| EP1819331A1 (en) | 2007-08-22 |
| SI1819331T1 (sl) | 2010-02-26 |
| JO2596B1 (en) | 2011-02-27 |
| TNSN07212A1 (en) | 2008-11-21 |
| JP2008521826A (ja) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200630091A (en) | Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof | |
| WO2011046964A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2008121742A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| WO2006004833A3 (en) | Pyrrolotriazine kinase inhibitors | |
| AU2006226897B2 (en) | Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors | |
| AP2332A (en) | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors. | |
| NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
| HK1139036A1 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| TW200801008A (en) | Protein kinase inhibitors | |
| IL173380A0 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| ATE542823T1 (de) | 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
| GB0421525D0 (en) | Inhibitors of protein kineses | |
| WO2006124684A3 (en) | Combination therapy comprising a taxane and a thymidylate synthase inhibitor | |
| WO2006052810A3 (en) | Combination of a src kinase inhibitor and a bcr-abl inhibitor for the treatment of proliferative diseases | |
| WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
| EP1922086A4 (en) | TARGETED PROTEIN KINASE C HEMMER AND ITS USES | |
| WO2007086943A3 (en) | Wortmannin conjugates and uses thereof | |
| WO2007050673A3 (en) | Cyclin dependent kinase inhibitors | |
| TNSN07025A1 (en) | Epothilone combinations | |
| ZA200704971B (en) | Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases | |
| WO2007010013A3 (en) | Combination comprising a pyrimidylaminobenzamides and a flt-3 inhibitor for treating proliferative diseases | |
| AU2005907140A0 (en) | Use of Naltrexone for Treating Alzheimers Disease |